ORYZON to present new data on its anti-neurodegenerative drug ORY-2001 at the International Conference on Multiple Sclerosis ECTRIMS-ACTRIMS

MADRID, SPAIN and CAMBRIDGE MA.

• The Poster has been shortlisted for the MSParis2017 Best Poster Award

Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its Chief Scientific Officer, Dr. Tamara Maes, will present new data on preclinical efficacy of ORY-2001 at MSParis2017, the joint meeting of ECTRIMS and ACTRIMS, the European and Americas Committees for Treatment and Research in Multiple Sclerosis, to be held in Paris, France on 25-28 October.

Click here to see the full Press Release